{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:57:02Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 18.4, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09542-3d8c-7f00-85fc-1c7f457dbff1\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: levodropropizine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 100", "usd": 0.0, "recall": true }, "codex": { "seconds": 81.4, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09542-3d80-7c02-8af2-4930fab09dbf\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: levodropropizine\nRegistry id: vr.tr.levodropropizine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry:" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:48:47+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q408131", "registryId": "vr.tr.levodropropizine", "name": "levodropropizine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q408131/", "model": { "registry_id": "vr.tr.levodropropizine", "name": "levodropropizine", "purpose": "Enable an agent to recognise levodropropizine, assess the identity and quality of a material sample, and determine which handling or use decisions require further evidence.", "definition": "Levodropropizine is the (S)-enantiomer of dropropizine, a small-molecule pharmaceutical substance used as a predominantly peripherally acting antitussive for symptomatic relief of nonproductive cough.", "scope_statement": "This model owns the substance identity of levodropropizine (vr.tr.levodropropizine; PHY / PHY.MAT), its stereochemical specificity, material quality, condition-dependent properties, and evidence linking it to permitted uses.", "in_scope": [ "Molecular identity and distinction from racemic dropropizine", "Chemical assay, enantiomeric composition, impurities, and material grade", "Physical form, measured properties, stability, and storage condition", "Substance-level pharmacological role and limits of supporting evidence", "Chemical safety and jurisdiction-specific identity and use restrictions" ], "out_of_scope": [ "Finished syrups, tablets, brands, excipients, and packaging specifications", "Patient diagnosis, prescribing, dose selection, and treatment monitoring", "Manufacturing plants and detailed synthesis process execution", "Racemic dropropizine or the opposite enantiomer as independently modelled substances", "Clinical trial operations and commercial marketing authorisations as standalone entities" ], "distinguishing_features": [ "Require the S configuration of the stereocentre: levodropropizine is the S-enantiomer of dropropizine, whereas dropropizine is racemic. [Comparative study](https://pubmed.ncbi.nlm.nih.gov/1295724/)", "Match the structure of (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol; molecular formula alone cannot distinguish its enantiomer. [PubChem identity](https://pubchem.ncbi.nlm.nih.gov/compound/Levodropropizine)", "Cross-check CAS 99291-25-5 and PubChem CID 65859 against the structure rather than accepting a trade name as substance identification. [PubChem identifiers](https://pubchem.ncbi.nlm.nih.gov/compound/Levodropropizine)", "Distinguish the active substance from a medicinal preparation containing it: a syrup concentration identifies a formulation property, not the purity of bulk levodropropizine. [Registered product information](https://verification.fda.gov.ph/files/DRP-11632-01_PI_01.pdf)" ], "characteristics": [ { "name": "Molecular composition", "kind": "category", "unit_or_values": "C13H20N2O2; molar mass 236.31 g/mol", "why_it_matters": "Supports composition checks and mass-to-amount conversion for the identified substance. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Levodropropizine)" }, { "name": "Stereochemical identity", "kind": "category", "unit_or_values": "S configuration; confirmed, inconsistent, or unverified", "why_it_matters": "Separates levodropropizine from its opposite enantiomer and racemic dropropizine." }, { "name": "Enantiomeric composition", "kind": "measurement", "unit_or_values": "S and R fractions in %; enantiomeric excess in %, with method and detection limits", "why_it_matters": "A chemical assay alone may not establish whether the material meets a stereochemical specification." }, { "name": "Levodropropizine assay", "kind": "measurement", "unit_or_values": "% mass fraction, with as-is, dried, or anhydrous basis", "why_it_matters": "Makes potency and purity statements comparable without silently changing the reporting basis." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in % or mg/kg; residual solvents in mg/kg; method-specific limits", "why_it_matters": "Distinguishes acceptable material from material containing excessive process residues or degradation products." }, { "name": "Material form and grade", "kind": "category", "unit_or_values": "Observed phase; identified solid form if established; water or solvent association; declared grade and specification", "why_it_matters": "Prevents unverified transfer of properties or suitability between different material presentations." }, { "name": "Condition-dependent physical properties", "kind": "measurement", "unit_or_values": "Melting range in °C; solubility in g/L at stated temperature, solvent, and pH; boiling or decomposition behaviour with pressure", "why_it_matters": "Supports handling and analytical preparation without treating unsourced constants as universal values." }, { "name": "Storage and retest status", "kind": "state", "unit_or_values": "Within specified conditions, excursion recorded, retest due, or unknown", "why_it_matters": "Connects current material suitability to its storage history and stability evidence." }, { "name": "Pharmacological role", "kind": "category", "unit_or_values": "Peripherally acting antitussive", "why_it_matters": "Identifies its established functional class without implying an individual treatment decision. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Levodropropizine)" }, { "name": "Applicable safety and regulatory records", "kind": "relation", "unit_or_values": "Linked SDS, classification record, substance register, and relevant product authorisation; jurisdiction and revision date", "why_it_matters": "Separates chemical handling requirements from permission to supply or administer a particular medicine." } ], "affordances": [ "Resolve a supplier's declared material to the stereochemically specific registry identity", "Request chemical and chiral analyses appropriate to the intended material grade", "Compare batch evidence with a cited specification and flag missing acceptance criteria", "Assess whether storage excursions require quarantine or retesting", "Find applicable handling requirements and route clinical or product decisions to neighbouring models" ], "agent_conduct": { "may": [ "Describe levodropropizine and its approved uses from medicines information.", "Report the country-specific authorization status, which differs between markets." ], "must_not": [ "Recommend it or a dose for a specific person.", "Present it as suitable for productive cough or for infants when the labelling says otherwise.", "Suggest it as a substitute for medical assessment of a long-lasting cough." ], "requires_human": [ "Deciding to give it to a child, pregnant woman or person with other conditions." ] }, "ethics": { "considerations": [ "A persistent cough can signal serious illness that symptom relief may mask.", "Authorization differs between countries, so advice from one place can mislead in another." ], "affected_parties": [ "Patients with cough", "Parents of children" ] }, "owners": { "steward": "The marketing authorization holder; medicines regulators decide where it may be sold.", "master_systems": [ "Medicines regulators' product registers" ] }, "visual_identification": [ "Supplied as syrup, drops or tablets; identified by its label, not appearance." ], "failure_modes_and_hazards": [ "Suppressing a productive cough can retain secretions.", "Can cause drowsiness and other adverse effects." ], "what_it_is_for": [ "Levodropropizine is used as an antitussive medicine for symptomatic relief of nonproductive cough.", "It is encountered as a pharmaceutical ingredient, in finished medicines and in analytical laboratories assessing identity and quality." ], "standards_and_regulation": [ "The WHO Collaborating Centre for Drug Statistics Methodology classifies levodropropizine under ATC code R05DB27 within other cough suppressants." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q408131: levodropropizine", "url": "https://www.wikidata.org/wiki/Q408131", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Levodropropizine", "url": "https://en.wikipedia.org/wiki/Levodropropizine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "substance-and-stereochemistry", "name": "Substance and stereochemistry", "description": "Establish exactly which molecular entity the levodropropizine entry represents.", "rationale": "Its relationship to racemic dropropizine makes stereochemistry essential to recognition.", "layers": [ { "id": "molecular-identity", "name": "Molecular identity", "description": "Resolve identifiers against a stereochemically explicit structure.", "findings": [ { "id": "identity-agreement", "name": "Identity agreement", "description": "Record whether the name, identifier, and supplied structure consistently identify levodropropizine.", "questions": [ { "text": "Does the supplied structure specify the S configuration of (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol?", "kind": "definition", "id": "identity-agreement-q01" }, { "text": "Which authoritative record supports the identifier-to-structure mapping, and when was it checked?", "kind": "provenance", "id": "identity-agreement-q02" } ] } ] }, { "id": "racemate-and-product-boundaries", "name": "Racemate and product boundaries", "description": "Separate the registered substance from stereochemical mixtures and preparations.", "findings": [ { "id": "represented-entity", "name": "Represented entity", "description": "Determine whether a record describes levodropropizine itself, racemic material, a chemically modified form, or a formulated product.", "questions": [ { "text": "Does the record describe the S-enantiomer, racemic dropropizine, or material whose stereochemistry remains unspecified?", "kind": "boundary", "id": "represented-entity-q01" }, { "text": "Is a claimed concentration or identifier attached to the active substance, a salt, or a finished medicine?", "kind": "boundary", "id": "represented-entity-q02" } ] } ] } ] }, { "id": "assay-and-chiral-quality", "name": "Assay and chiral quality", "description": "Assess bulk material using separate chemical and stereochemical evidence.", "rationale": "High total assay does not by itself establish the required enantiomeric composition.", "layers": [ { "id": "chemical-content", "name": "Chemical content", "description": "Establish assay and impurity results on a stated analytical basis.", "findings": [ { "id": "batch-assay-and-residues", "name": "Batch assay and residues", "description": "Keep levodropropizine content, related substances, and residual solvents distinguishable.", "questions": [ { "text": "What levodropropizine assay was measured, by which method, and on what moisture or drying basis?", "kind": "measurement", "id": "batch-assay-and-residues-q01" }, { "text": "Which impurity and residual-solvent limits apply to this grade, and which results remain unreported?", "kind": "provenance", "id": "batch-assay-and-residues-q02" } ] } ] }, { "id": "enantiomeric-control", "name": "Enantiomeric control", "description": "Evaluate evidence that distinguishes S and R material.", "findings": [ { "id": "chiral-acceptance", "name": "Chiral acceptance", "description": "Treat stereochemical acceptance as an explicit decision supported by a suitable method.", "questions": [ { "text": "What S:R ratio or enantiomeric excess was measured, and can the method resolve and quantify the opposite enantiomer?", "kind": "measurement", "id": "chiral-acceptance-q01" }, { "text": "Which specification defines the permissible opposite-enantiomer content and the disposition of a failing batch?", "kind": "action", "id": "chiral-acceptance-q02" } ] } ] } ] }, { "id": "physical-condition-and-stability", "name": "Physical condition and stability", "description": "Describe the actual material and the conditions under which its properties remain applicable.", "rationale": "Handling and suitability depend on measured form and storage history, not only molecular identity.", "layers": [ { "id": "form-and-properties", "name": "Form and properties", "description": "Connect physical measurements to the tested levodropropizine sample.", "findings": [ { "id": "qualified-property-values", "name": "Qualified property values", "description": "Record physical constants with material form, conditions, and experimental or predicted status.", "questions": [ { "text": "What phase and solid-form identity, if established, describe the sample used for the property measurement?", "kind": "measurement", "id": "qualified-property-values-q01" }, { "text": "What evidence supports its melting range, solubility, and boiling or decomposition behaviour under stated conditions?", "kind": "provenance", "id": "qualified-property-values-q02" } ] } ] }, { "id": "storage-history", "name": "Storage history", "description": "Assess whether the material remains within supported stability conditions.", "findings": [ { "id": "continued-material-suitability", "name": "Continued material suitability", "description": "Relate observed changes and excursions to batch-specific retest or quarantine decisions.", "questions": [ { "text": "Which temperature, humidity, light, and container conditions are supported for this grade of levodropropizine?", "kind": "provenance", "id": "continued-material-suitability-q01" }, { "text": "Does an excursion or changed analytical profile trigger retesting or quarantine under the applicable specification?", "kind": "action", "id": "continued-material-suitability-q02" } ] } ] } ] }, { "id": "antitussive-role-and-evidence", "name": "Antitussive role and evidence", "description": "Link the substance to pharmacological evidence without embedding prescribing decisions.", "rationale": "The antitussive role helps identify intended use, while mechanism and clinical claims require different evidence.", "layers": [ { "id": "pharmacological-interpretation", "name": "Pharmacological interpretation", "description": "Separate supported functional classification from detailed mechanistic hypotheses.", "findings": [ { "id": "mechanism-evidence-boundary", "name": "Mechanism evidence boundary", "description": "Retain the evidence type and uncertainty behind claims about peripheral antitussive action.", "questions": [ { "text": "Which evidence supports a peripheral antitussive effect specifically for levodropropizine?", "kind": "provenance", "id": "mechanism-evidence-boundary-q01" }, { "text": "Which proposed nerve, mediator, or molecular-target effects remain hypotheses rather than established mechanisms?", "kind": "definition", "id": "mechanism-evidence-boundary-q02" } ] } ] }, { "id": "clinical-transfer-boundary", "name": "Clinical transfer boundary", "description": "Prevent substance-level evidence from becoming an unsupported product or patient recommendation.", "findings": [ { "id": "evidence-applicability", "name": "Evidence applicability", "description": "Associate efficacy and safety findings with the actual substance, formulation, population, and study conditions.", "questions": [ { "text": "Was the cited result obtained with levodropropizine, racemic dropropizine, or a combination product?", "kind": "boundary", "id": "evidence-applicability-q01" }, { "text": "Which formulation, population, and clinical-context limitations must accompany a handoff to a treatment model?", "kind": "action", "id": "evidence-applicability-q02" } ] } ] } ] }, { "id": "handling-and-regulatory-applicability", "name": "Handling and regulatory applicability", "description": "Determine which safety records and permissions apply to a specific material and proposed activity.", "rationale": "Bulk chemical handling and medicinal use require distinct, locally applicable evidence.", "layers": [ { "id": "bulk-material-safety", "name": "Bulk material safety", "description": "Resolve hazards for the supplied substance and its handling conditions.", "findings": [ { "id": "applicable-hazard-evidence", "name": "Applicable hazard evidence", "description": "Use current, substance-matched safety documentation without interpreting missing classifications as evidence of safety.", "questions": [ { "text": "Which SDS and jurisdictional GHS classification apply to the supplied levodropropizine material?", "kind": "provenance", "id": "applicable-hazard-evidence-q01" }, { "text": "What documented exposure limits or task-specific controls apply to weighing, dust generation, spills, and disposal?", "kind": "action", "id": "applicable-hazard-evidence-q02" } ] } ] }, { "id": "jurisdiction-and-intended-use", "name": "Jurisdiction and intended use", "description": "Link proposed activities to the relevant substance records and product permissions.", "findings": [ { "id": "permission-scope", "name": "Permission scope", "description": "Keep identity registration, grade compliance, and medicinal product authorisation separate.", "questions": [ { "text": "Which jurisdiction, date, and intended activity govern whether this levodropropizine material may be supplied or used?", "kind": "boundary", "id": "permission-scope-q01" }, { "text": "What authoritative record supports that permission, and does it apply to the substance or only to a specified medicinal product?", "kind": "provenance", "id": "permission-scope-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information, without consulted sources; identifiers should be verified before registry publication.", "Its peripheral antitussive action is established terminology, but a precise molecular mechanism should not be asserted without checking the evidence.", "Purity specifications, solid-state properties, GHS classification and jurisdiction-specific product restrictions require verification." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of levodropropizine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "levodropropizine", "note": "Generic name for the active substance, distinct from branded formulations." }, { "scheme": "CAS Registry Number", "value_or_pattern": "99291-25-5", "note": "Identifies levodropropizine with its specified stereochemistry." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "R05DB27", "note": "Classified among other cough suppressants." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of levodropropizine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Active ingredient in oral medicines for symptomatic relief of dry, nonproductive cough." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of levodropropizine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of the neutral molecule, C13H20N2O2", "typical_range": "236.31", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of levodropropizine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Dizziness or somnolence can occur.", "Gastrointestinal adverse effects can occur.", "Hypersensitivity reactions are possible.", "Suppressing cough when clearance of respiratory secretions is needed can be inappropriate.", "Symptomatic cough suppression does not treat the underlying cause of cough." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of levodropropizine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Marketing authorization, available formulations, age restrictions and prescription status depend on jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of levodropropizine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "dropropizine", "difference": "Dropropizine is the racemic substance; levodropropizine is its (S)-enantiomer." }, { "name": "dextromethorphan", "difference": "Dextromethorphan is a chemically distinct antitussive with predominantly central action." }, { "name": "levodropropizine oral solution", "difference": "An oral solution is a formulated medicinal product containing levodropropizine plus excipients; levodropropizine itself is the active substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of levodropropizine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which current pharmacopoeial or other authoritative specifications define levodropropizine assay, opposite-enantiomer content, related substances, and accepted analytical methods?", "Which experimentally supported physical constants, solid forms, and stability conditions apply to the free substance, and does thermal decomposition preclude a meaningful boiling-point value?", "What EC identifier, jurisdiction-specific GHS classifications, and occupational exposure limits can be verified for the exact substance?", "How firmly are the proposed peripheral mechanisms established, and which claims rely principally on preclinical evidence?", "Which current jurisdiction-specific product authorisations and restrictions are relevant to the intended use, and what limits prevent transferring them to another formulation or material grade?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }